On Nov. 11, 2020, the Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) announced completion of enrollment of phase 3 clinical trials for COVISHIELD in India. ICMR and SII had further collaborated for clinical development COVOVAX (Novavax) developed by Novavax in the U.S. and upscaled by SII.